Abstracts tagged "Disease Activity"

Abstract Number: 2683 • 2015 ACR/ARHP Annual Meeting
Contribution of Subjective Patient Reported Components of Disease Activity Scores Differs in Disease Activity Measures and Their Changes over Time Are Closely Associated with Objective Measures
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio³ and Larry W. Moreland⁴, ¹Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Patient reported measures are influenced by many non-rheumatoid arthritis (RA) factors and they are reflected variably among various composite disease activity scores (DAS). We…
Abstract Number: 3147 • 2015 ACR/ARHP Annual Meeting
Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease
Janalee Taylor¹, Edward H. Giannini¹, Daniel Lovell² and Esi M. Morgan DeWitt¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: With the advent and implementation of advanced drug therapy clinical inactive disease (CID) has become an attainable target in the treatment of juvenile idiopathic…
Abstract Number: 267 • 2015 ACR/ARHP Annual Meeting
Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease
Hyoun-Ah Kim¹, In Je Kim², Jae Ho Han³, Chang-Hee Suh¹ and Juyang Jung¹, ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, ³Department of Pathology, Ajou University School of Medicine, Suwon, South Korea
Background/Purpose: CXCL10 is produced in response to interferon-γ, and tumor necrosis factor-α (TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary…
Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting
Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis
Masao Sato¹ and Masao Takemura², ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Matsunami Reserch Park, Gifu, Japan
Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
Abstract Number: 867 • 2015 ACR/ARHP Annual Meeting
Simultaneous Measurement of 25-Hydroxyvitamin D and Procalcitonin in Granulomatosis with Polyangiitis (GPA): Differentiation of Activity from Infection?
Mariana O Perez¹, Ricardo M. Oliveira², Valéria Caparbo^3,4, Mauricio Levy-Neto⁵, Eloisa Bonfá⁴ and Rosa M R Pereira³, ¹Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²RDO Diagnósticos Médicos, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology DIvision, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Vitamin D acts as innate and adaptive immune response immunomodulator. 25-hydroxyvitamin D (25OHD) deficiency was reported to be associated with autoimmune diseases flares and…
Abstract Number: 1637 • 2015 ACR/ARHP Annual Meeting
TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis
Leslie Harrold^1,2, George W. Reed^1,2, Natalie Boytsov³, Carol L. Gaich³, Marc Mason⁴, Xiang Zhang³, Cynthia J. Larmore³, Sabrina Deveikis⁴ and Andre B. Araujo³, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: The purpose of this study was to describe the treatment patterns in biologic naïve initiators of TNF-inhibitors (TNFi) based on their disease activity over…
Abstract Number: 2321 • 2015 ACR/ARHP Annual Meeting
Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort
Hélène Che¹, Bernard Combe², Jacques Morel³, Alain G. Cantagrel⁴, Laure Gossec⁵ and Cédric Lukas⁶, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Rheumatology, Hopital Lapeyronie, Montpellier, France, ³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose: Activity of rheumatoid arthritis (RA) can be assessed by several outcome measures : joint counts, inflammatory syndrom but also auto-questionnaires such as global patient…
Abstract Number: 2605 • 2015 ACR/ARHP Annual Meeting
14-3-3η Positive Status and Higher Titres Are Associated with More Severe RA
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Serum 14-3-3η is an RA diagnostic marker that is associated with radiographic progression risk. In vitro studies describe 14-3-3η's potent, dose-dependent up-regulation of factors…
Abstract Number: 2740 • 2015 ACR/ARHP Annual Meeting
ACPA Positivity in the Elderly and Concomitant MTX Use in Younger May be Useful Predictive Factors for Superior Clinical Efficacy with Abatacept in Japanese Biological-Naïve RA Patients
Masahiro Sekiguchi¹, Takao Fujii², Masayasu Kitano¹, Kiyoshi Matsui¹, Kenji Miki³, Hideo Hashimoto⁴, Akira Yokota⁵, Aihiro Yamamoto⁶, Takashi Fujimoto⁷, Toshihiko Hidaka⁸, Naoki Shimmyo⁹, Keiji Maeda¹⁰, Takanori Kuroiwa¹¹, Ichiro Yoshii¹², Kosaku Murakami¹³, Koichiro Ohmura¹³, Satoshi Morita¹⁴, Yutaka Kawahito⁶, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁶ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Dept of Rheum/Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁴Rheumatology, Rinku Hashimoto Rheumatology Orthopaedics, Izumisano Osaka, Japan, ⁵Yokota Clinic for Rheumatology, Osaka, Japan, ⁶Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁷Nara Medical University, Kashihara, Japan, ⁸Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ⁹Department of Rheumatology, Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹⁰Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ¹¹Department of Internal Medicine, Yukioka Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Rheumatology & Clin Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁴Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Osaka Rheumatology Clinic, Osaka, Japan, ¹⁶Dept of Rheum & Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Sustained clinical remission is crucial in the RA. However, baseline predicting factors for sustained clinical remission in RA patients treated with abatacept (ABT) are…
Abstract Number: 3183 • 2015 ACR/ARHP Annual Meeting
The Clinical and Economic Costs of Not Achieving Remission in Rheumatoid Arthritis
Jeffrey R. Curtis¹, Lang Chen^1,2, Meredith Kilgore³, Huifeng Yun⁴ and Jeffrey D. Greenberg⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Bimingham, Birmingham, AL, ³Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Corrona, LLC, Southborough, MA
Background/Purpose: Treat to target guidelines recommend achieving a state of remission or low disease activity for rheumatoid arthritis (RA) patients. However, the benefit of lower…
Abstract Number: 2828 • 2014 ACR/ARHP Annual Meeting
A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis
Sofia Ramiro^1,2, A.M. van Tubergen³, Robert Landewé^4,5, Annelies Boonen⁶, Carmen Stolwijk⁷, Maxime Dougados⁸, Filip van Den Bosch⁹ and Desiree van der Heijde¹⁰, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ³Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁸Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁹Ghent University Hospital, Ghent, Belgium, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have recently shown that disease activity is longitudinally associated with radiographic progression in AS. In animal models, it has recently been shown that…
Abstract Number: 2456 • 2014 ACR/ARHP Annual Meeting
Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression
Marshall Davis¹, Tricia LeVan², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Kaleb Michaud⁷, Geoffrey M Thiele⁸ and Ted R. Mikuls⁴, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Univ of Nebraska Med Ctr, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷National Data Bank for Rheumatic Diseases, Wichita, KS, ⁸Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA). In this study,…
Abstract Number: 1921 • 2014 ACR/ARHP Annual Meeting
The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus
Joan T. Merrill¹, Aikaterini Thanou², Stan Kamp¹, John Conklin³, Derren Barken⁴ and Thierry Dervieux⁵, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: We sought to evaluate the usefulness of cell bound complement activation products (C4d deposition on erythrocytes [EC4d] and platelets [PC4d]) in the monitoring of…
Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Yomei Shaw¹, Chung-Chou H. Chang², Marc C. Levesque³, Julie M. Donohue⁴, Kaleb Michaud^5,6 and Mark S. Roberts¹, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ⁴Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
Abstract Number: 1053 • 2014 ACR/ARHP Annual Meeting
Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis
Christopher Sparks¹, Aleena Abdullah², Steven Zhao³, Cristina Estrach³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Musculoskeletal biology1, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, University Hospital Aintree, Liverpool, United Kingdom
Background/Purpose Co-morbidity has been shown to increase length of hospital stay and mortality in hospitalised patients. However, in early rheumatoid arthritis (eRA) co-morbidity may confound…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].